The tumor suppressor p53: Cancer and aging

Cell Cycle

Volumn 7, Issue 7, 2008, Pages 842-847

  Feng, Zhaohui ^a   Hu, Wenwei ^a   Rajagopal, Gunaretnam ^a,b   Levine, Arnold J ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

Cancer; Longevity; p53; Stress response; Tumor suppressor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; SOMATOMEDIN C;

AGING; CALORIC RESTRICTION; GENE MUTATION; HUMAN; LIFESPAN; LONGEVITY; NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW;

ANIMALIA; MUS;

EID: 42449152382     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.7.5657     Document Type: Review

References (53)

1. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philosophical Transactions of the Royal Society of London 1825; 115:513-85.
2. Wilson DL. The analysis of survival (mortality) data: fitting Gompertz, Weibull, and logistic functions. Mech Ageing Dev 1994; 74:15-33.
3. Finch C. Longevity, Senescense and the Genome. (University of Chicago Press, Chicago) 1990.
4. Arking R. The Biology of Aging: Observation & Principles. 3rd ed. (Oxford University Press, New York) 2006.
5. Geiger Thornsberry GL and Mackay TF. Quantitative trait loci affecting natural variation in Drosophila longevity. Mech Ageing Dev 2004; 125:179-89.
6. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005; 120:449-60.
7. Guarente L. Calorie restriction and SIR2 genes - towards a mechanism. Mech Ageing Dev 2005; 126:923-8.
8. Levine AJ, Feng Z, Mak TW, You H and Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75.
9. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V and Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004; 14:885-90.
10. Kusama S, Ueda R, Suda T, Nishihara S and Matsuura ET. Involvement of Drosophila Sir2-like genes in the regulation of life span. Genes Genet Syst 2006; 81:341-8.
11. Kaeberlein M, Powers RW, 3rd, Steffen KK, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S and Kennedy BK. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005; 310:1193-6.
12. Fabrizio P, Gattazzo C, Battistella L, Wei M, Cheng C, McGrew K and Longo VD. Sir2 blocks extreme life-span extension. Cell 2005; 123:655-67.
13. Cohen HJ. Biology of aging as related to cancer. Cancer 1994; 74:2092-100.
14. Balducci L and Beghe C. Cancer and age in the USA. Crit Rev Oncol Hematol 2001; 37:137-45.
15. Campisi J. Cancer, aging and cellular senescence. In Vivo 2000; 14:183-8.
16. Albert RE, Benjamin SA and Shukla R. Life span and cancer mortality in the beagle dog and humans. Mech Ageing Dev 1994; 74:149-59.
17. Anisimov VN. Life span extension and cancer risk: myths and reality. Exp Gerontol 2001; 36:1101-36.
18. Sgro CM and Partridge L. A delayed wave of death from reproduction in Drosophila. Science 1999; 286:2521-4.
19. Sharpless NE and DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 8:703-13.
20. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley A and Donehower LA. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415:45-53.
21. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M and Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004; 18:306-19.
22. Hu W, Feng Z, Teresky AK and Levine AJ. p53 regulates maternal reproduction through LIF. Nature 2007; 450:721-4.
23. Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA and Donehower LA. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 2007; 109:1736-42.
24. Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, Lowe S, Prives C and Levine AJ. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 2006; 25:1-7.
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
26. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7.
27. Levine AJ, Hu W and Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006; 13:1027-36.
28. Harris SL and Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24:2899-908.
29. Stommel JM and Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. Embo J 2004; 23:1547-56.
30. Feng Z, Zhang H, Levine AJ and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204-9.
31. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S and Levine AJ. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007; 67:3043-53.
32. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68.
33. Sarbassov DD, Ali SM and Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17:596-603.
34. Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res 2002; 35:305-13.
35. Inoki K, Zhu T and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-90.
36. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T and Thompson CB. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120:237-48.
37. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-8.
38. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
39. Yamada M, Udono MU, Hori M, Hirose R, Sato S, Mori T and Nikaido O. Aged human skin removes UVB-induced pyrimidine dimers from the epidermis more slowly than younger adult skin in vivo. Arch Dermatol Res 2006; 297:294-302.
40. Vyjayanti VN and Rao KS. DNA double strand break repair in brain: reduced NHEJ activity in aging rat neurons. Neurosci Lett 2006; 393:18-22.
41. Woodland DL and Blackman MA. Immunity and age: living in the past? Trends Immunol 2006; 27:303-7.
42. Feng Z, Hu W, Teresky AK, Hernando E, Cordon Cardo C and Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007; 104:16633-8.
43. Goodrick CL. Life-span and the inheritance of longevity of inbred mice. J Gerontol 1975; 30:257-63.
44. Turturro A, Witt WW, Lewis S, Hass BS, Lipman RD and Hart RW. Growth curves and survival characteristics of the animals used in the Biomarkers of Aging Program. J Gerontol A Biol Sci Med Sci 1999; 54:492-501.
45. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, Stolovitzky G and Levine AJ. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007; 67:2757-65.
46. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405:486-9.
47. Hande MP, Balajee AS, Tchirkov A, Wynshaw Boris A and Lansdorp PM. Extra-chromosomal telomeric DNA in cells from Atm(-/-) mice and patients with ataxia-telangiectasia. Hum Mol Genet 2001; 10:519-28.
48. Garcia Cao I, Garcia Cao M, Martin Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA and Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. Embo J 2002; 21:6225-35.
49. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA and Perry ME. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006; 20:16-21.
50. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE and Westendorp RG. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 2005; 40:11-5.
51. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65.
52. Smetannikova MA, Beliavskaia VA, Smetannikova NA, Savkin IV, Denisova DV, Ustinov SN, Maksimov VN, Shabalin AV, Bolotnova TV and Voevoda MI. [Functional polymorphism of p53 and CCR5 genes in the long-lived of the Siberian region]. Vestn Ross Akad Med Nauk 2004; 25-8.
53. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K and Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-10.